|
SUB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
1.55260004852664E-09 |
| Normal-vs-Stage3 |
1.83508763740292E-12 |
| Normal-vs-Stage4 |
1.63136171238421E-12 |
| Stage1-vs-Stage2 |
7.963200E-01 |
| Stage1-vs-Stage3 |
4.675000E-01 |
| Stage1-vs-Stage4 |
9.741700E-03 |
| Stage2-vs-Stage3 |
4.874800E-01 |
| Stage2-vs-Stage4 |
1.847520E-02 |
| Stage3-vs-Stage4 |
8.947700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.379800E-04 |
| Normal-vs-Asian |
1.54819490560953E-11 |
| Caucasian-vs-AfricanAmerican |
4.396000E-01 |
| Caucasian-vs-Asian |
8.573000E-01 |
| AfricanAmerican-vs-Asian |
4.200000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.22124532708767E-15 |
| Normal-vs-Female |
1.62558855265615E-12 |
| Male-vs-Female |
2.763800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.68265401612189E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.94280147525205E-11 |
| Normal-vs-Age(81-100Yrs) |
3.374600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.236000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.583600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.063700E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.309600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.941500E-03 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.375590E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.345670E-02 |
| Classical-VS-Follicular |
6.319800E-01 |
| Classical-VS-Other |
4.865000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.080460E-02 |
| Tall-VS-Other |
5.998800E-01 |
| Tall-VS-Normal |
4.96203078625967E-12 |
| Follicular-VS-Other |
4.814000E-01 |
| Follicular-VS-Normal |
5.15450004900941E-09 |
| Other-VS-Normal |
4.151700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.65023591750469E-14 |
| Normal-vs-N1 |
9.99755833674953E-13 |
| N0-vs-N1 |
1.610390E-01 |
|
|
